Virax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report)’s stock price shot up 8.2% during trading on Tuesday. The stock traded as high as $2.65 and last traded at $2.50. 50,988 shares traded hands during mid-day trading, an increase of 32% from the average daily volume of 38,563 shares. The stock had previously closed at $2.31.
Analyst Ratings Changes
Several equities analysts recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Virax Biolabs Group in a research report on Monday, July 6th. Wall Street Zen raised Virax Biolabs Group from a “sell” rating to a “hold” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Virax Biolabs Group presently has a consensus rating of “Hold” and an average price target of $25.00.
Check Out Our Latest Stock Analysis on VRAX
Virax Biolabs Group Price Performance
Virax Biolabs Group (NASDAQ:VRAX – Get Free Report) last issued its earnings results on Friday, July 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.75) by $1.55. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. On average, research analysts forecast that Virax Biolabs Group Limited will post -6 EPS for the current year.
Virax Biolabs Group Company Profile
Virax Biolabs Group Limited is a biotechnology company focused on the prevention, detection and diagnosis of viral diseases. The company develops and commercializes diagnostic technologies intended to help identify infections and assess immune responses to viral pathogens.
Its portfolio includes molecular diagnostic products and immune-profiling technologies designed to measure T-cell responses to specific viruses. These products are intended for use by healthcare providers, laboratories and other organizations involved in infectious-disease testing and monitoring.
Virax Biolabs is headquartered in the United Kingdom and has pursued international commercialization and distribution opportunities for its diagnostic products.
Further Reading
- Five stocks we like better than Virax Biolabs Group
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Virax Biolabs Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virax Biolabs Group and related companies with MarketBeat.com's FREE daily email newsletter.
